(Q43271774)

18 November 2017

title

Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function (English)

1 reference

18 November 2017

1 reference

Reza Khosravan

1

1 reference

18 November 2017

Melvin Toh

2

1 reference

18 November 2017

May Garrett

3

1 reference

18 November 2017

Joann La Fargue

4

1 reference

18 November 2017

Grace Ni

5

1 reference

18 November 2017

Thomas C Marbury

6

1 reference

18 November 2017

Suzanne K Swan

7

1 reference

18 November 2017

Norman M Lunde

8

1 reference

18 November 2017

Carlo L Bello

9

1 reference

18 November 2017

publication date

24 September 2009

1 reference

The Journal of Clinical Pharmacology

18 November 2017

published in

1 reference

18 November 2017

volume

50

1 reference

18 November 2017

issue

4

1 reference

18 November 2017

page(s)

472-481

1 reference

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

Systemic diseases with renal manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

Altered nonrenal drug clearance in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347868

21 January 2018

Identifiers

DOI

10.1177/0091270009347868

1 reference

18 November 2017

1 reference